R. Agha, Editorial Office, International Journal of Surgery, Surgical Associates Ltd., 167 Earls Court Road, London, UK
After being awarded 4 A's at A-level in 1998, he went to work for Harrods in Knightsbridge,
London, for 1 year, following which he entered medical school. During his first two years he was awarded the Pre-Clinical Scholarship,
the Distinction in Basic Medical Sciences and the Pickering Prize. Riaz also worked as a Student Ambassador for King's College London,
as a Medical Secretary and as the PA for the Manager of the Surgical Directorate over the summer months of 2000, 2001 and 2002, in a
number of departments and hospitals throughout London.
In September 2001, Riaz did an intercalated BSc(Hons) in Anatomy, in which
he gained a 1st and a PPP Foundation Scholarship. In the 4 months following his BSc, Riaz worked on gene cloning and protein analysis
at the Randall Centre for Biomolecular Sciences at King's College London, for which he was awarded a Wellcome Trust Vacation Scholarship.
In November 2002, Riaz became the National Coordinator for the CPR in Schools Project, which aims to teach school children basic
life support skills to improve myocardial infarction survival rates. In January 2003, Riaz became a Student Advisor for the Student BMJ
and a member of the local BMA Committee. In March, Riaz became the President of the Guy's, King's and St. Thomas ' Surgical Society,
which under his leadership became the largest surgical society in the UK . For his work with the Surgical Society, as President of the
King's College London Chess Team and Vice-President of the Salsa Society, Riaz was acknowledged with a Gold Medal and a Student Activities
Award by the King's College London Student's Union in May.
In June, Riaz became an Associate for Medical
Futures and also completed the SimfonecSimfonec Entrepreneurship
and Innovation Course. In July, he founded Surgical Associates Ltd and became its sole Director. In October, he launched the International
Journal of Surgery (IJS) with Surgical Associates Ltd as the Publisher.
Riaz published his first scientific paper in October 2003* and this was followed up by another in February 2004. He has also published a number of articles and letters in the popular medical media as well
as in the journal Medical Education, where his letter published in September
2003** proposed an original hypothesis which received a full
Editorial** in the journal. A full list of Riaz's publications are shown here.
In 2003, Riaz also presented his surgical research at International Scientific meetings held in April at the British Association
of Rheumatology, Manchester , in June at the European Federation of National Associations of Orthopaedics and Traumatology and in November
at the 5th International Congress on Surgery for Students, Santiago de Compostela. In addition, he has also presented at a number of
other national, regional and local meetings. In October, Riaz was a speaker at the surgical
debate on medical education held by the Section of Surgery at the Royal Society of Medicine (Riaz argued against the motion
that day and his team won!).
In January 2004, Riaz became a Member of Council for the Section
of Plastic Surgery at the Royal Society of Medicine in London . Riaz was awarded 13 prizes for his elective in July 2004
at the Tissue Engineering and Wound Healing Laboratory at Harvard University . Whilst at Harvard, Riaz conducted research on the use
of micromechanical forces in wound healing and also worked on a number of other projects involving stem cells and work which was outsourced
to his lab by Biotechnology Companies. Riaz is also a coauthor on a number of papers to be published by the lab in due course. Riaz was
known as the 'Grantmaster' whilst at Harvard (in light of his own grant applications) and was also responsible for seeking out new grants
and for building grant proposals including one to NASA.
In September 2004, Riaz reviewed the 39th Edition of Gray's Anatomy at the editor'-in-Chief Professor Susan Standring's invitation, prior to its release in November 2004 (published
by Elsevier).
In June 2005, Riaz graduated from Guy's, King's and St. Thomas' School of Medicine - MBBS with distinctions.
In August, he will take up a post as a House Officer at Guy's and St. Thomas' NHS Foundation Trust.
M. Baum, Professor Emeritus of Surgery and visiting Prof. of Medical Humanities, University College London
Prof. Michael Baum MB, ChB, FRCS, ChM, MD(hc), FRCR(hon)
Current
position: Professor Emeritus of Surgery and visiting Prof. Of Medical Humanities, University College London.
Qualifications
MB ChB Birm 1960 Fellow Royal College Surgeons 1965 ChM (master of surgery) 1972 MD (hon) Gotenburg University 1986 Fellow
of the Royal College of Radiology (hon) 1998 Fellow Royal Society of Arts 1998
Previous appointments Surgical trainee
Kings College Hospital 1965 -1973 Research fellow University of Pittsburgh, PA 1973-1974 Senior lecturer/Reader in surgery University
Hospital of Wales 1974-1979 Professor of Surgery Kings College London 1980-1990 Director of CRC Clinical Trials Center 1980-1995
Professor of Surgery Royal Marsden Hospital and Institute of Cancer Research 1990-1996 Professor of Surgery University College London
( UCL) 1996-2000
Past and present leadership roles Chairman of UKCCCR breast cancer sub-committee 1987-1994 President
British Oncological Association 1996-1998 Chairman of Council National Institute Medical Humanities 1999- 2001 President 3rd
European Breast Cancer Conference 2002 Principle Investigator International ATAC collaboration investigating adjuvant endocrine therapy
for early breast cancer. 1996-2003 Chairman medical committee of AVMA (The Association for the Victims of Medical Accidents) 2000-
Chairman of the National Cancer Research Network Psycho-social Oncology Development Group 2003-
Awards Skinner Medal
- Royal College Radiologists Gold Medal- International College of Surgeons Ernest Miles Medal - Royal College of Surgeons
Celebrating Survival Award - San Antonio Breast Cancer Conference 2000 [One of ten awards given to those who had contributed most to
the survival of women with breast cancer over the previous 20 years.] Miami Breast Cancer conference award 2001 (A biennial
award for a life-time achievement in breast cancer research) Best of Oncology, American Society Clinical Oncology 2002 (One of four
awards given for the best contribution to cancer research over the previous 12 months) The William McGuire award, San Antonio, Texas
2002 (Annual award for a life-time achievement in breast cancer research) Charles Marie Gros Award of the International Society of
Senology (SIS) 2003 (Annual award for a life-time achievement in breast cancer research)
Innovations I established the
first multi-centre collaborative group for trials of treatment for breast cancer in 1970 and on the back of that the first purpose built
clinical trials centre in 1980. I established the first nurse counselling service at KCH in 1981 and the first psychosocial oncology
research team at the same time. With my colleague Dr Terry Priestman I developed the first instrument for measuring quality of life
in patients undergoing treatment for cancer (LASA). My group were also involved in developing the ethical models for randomised controlled
trials and the development of informed consent procedures. This also included a consumers advisory group. As Vice President of EUSOMA
I was in part instrumental in building up EUROPA DONNA and worked closely with this organization as President of the third European Breast
Cancer Conference 2002 in Barcelona. This lead to the Statement of Barcelona on behalf of EUSOMA, EORTC and EUROPA DONNA. My group
was the first to show the survival advantage of adjuvant tamoxifen, which has contributed to the 30% fall in breast cancer mortality
over the last 15 years. As a spin off from these trials we were also the first to note the potential of tamoxifen to prevent breast
cancer. Most recently I have put together the biggest International cancer trials group in history (ATAC), which in record time demonstrated
the superiority of Anastrozole to tamoxifen. Alongside this trial of over 9,000 patients we have a subcommittee responsible for collecting
and storing archival material for translational research that will relate the response of the aromatase inhibitors to various phenotypes
of breast cancer based on steroid and growth factor receptors. This trial also contributed 1,000 patients to a sub protocol measuring
quality of life chaired by Prof. Lesley Fallowfield. Finally my group have developed a novel technique for delivering radiotherapy
at the time of surgery which could save the NHS millions of pounds a year and opens up the way for women in the developing world to enjoy
the option of retaining their breasts after surgery for early breast cancer.
References 2004: Baum M.The endocrine management
of postmenopausal women with early breast cancer. Breast Cancer. 2004;11(1):15-9.
Baum M Making Amends misses the point. BMJ. 2004
Feb 14;328(7436):407.
Vaidya JS, Tobias JS, Baum M, Keshtgar M, Joseph D, Wenz F, Houghton J, Saunders C, Corica T, D'Souza D, Sainsbury
R, Massarut S, Taylor I, Hilaris B. Intraoperative radiotherapy for breast cancer. Lancet Oncol. 2004 Mar;5(3):165-73.
Baum M. Commentary:
false premises, false promises and false positives--the case against mammographic screening for breast cancer. Int J Epidemiol. 2004
Feb;33(1):66-7
Cuzick J, Buzdar A, Baum M, Bianco R, Coleman R, Constenla M, Distler W, Dowsett M, Forbes J, Guastalla JP, Houghton
J, Williams N, Howell A, Locker G, MacKey J, Sainsbury R, Tobias J. Adjuvant use of anastrozole in breast cancer. J Clin Oncol. 2004
Apr 15;22(8):1524-6
Tobias JS, Vaidya JS, Keshtgar M, D'Souza DP, Baum M. Reducing radiotherapy dose in early breast cancer: the
concept of conformal intraoperative brachytherapy. Br J Radiol. 2004 Apr;77(916):279-84
Fennessy M, Bates T, MacRae K, Riley D, Houghton
J, Baum M. Late follow-up of a randomized trial of surgery plus tamoxifen versus tamoxifen alone in women aged over 70 years with operable
breast cancer. Br J Surg. 2004 Jun;91(6):699-704.
Gray LC, Vaidya JS, Baum M, Badwe RA, Mittra I, Siddiqui T, Wiarda D. Functional
Maps of Metastases from Breast Cancers: Proof of the Principle that Multidimensional Scaling Can Summarize Disease Progression. World
J Surg. 2004 Jun 8
Vaidya JS, Tobias J, Baum M, Keshtgar M, Houghton J, Wenz F, Corica T, Joseph D. Intraoperative radiotherapy:
the debate continues. Lancet Oncol. 2004 Jun;5(6):339-40
Baum M. Does the act of surgery provoke activation of "latent" metastases
in early breast cancer? Breast Cancer Res. 2004;6(4):160-1. Epub 2004 Jun 09.
Baum M. The use and abuse of human tissue: an analysis
of the ethical issues raised by the proposed Human Tissue Act. Med Leg J. 2004;72(Pt 2):67-9
Baum M. Current Status of Aromatase
Inhibitors in the Management of Breast Cancer and Critique of the NCIC MA-17 Trial Cancer Control. 2004 Jul-Aug;11(4):217-21.
Jassem
J, Buchanan M, Janicke F, Baum M, Cataliotti L, Kyriakides S, Piccart M, Rutgers EJ, Costa A. The Hamburg statement: the partnership
driving the European agenda on breast cancer. Eur J Cancer. 2004 Aug;40(12):1810-1
Key References prior to 2004 The Statement
of Barcelona: The future of Breast Cancer Research in Danger. Baum M, Buchanan M, Baselga J, Cataliotti L, Jassem J, Piccart M European
Journal of Cancer, 2002, 38;2210-2213
The ATAC (Arimidex,Tamoxifen Alone or in Combination) Trialist group. Anastrozole alone or
in combination for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. The
Lancet 2002; 359: 2131-2139
Baum M, Chaplain M, Anderson A, Douek M, Vaidya JS. Does breast cancer exist in a state of chaos?
Eur J Cancer 1999; 35: 886-91.
Schipper H, Turley EA, Baum M. A new biological framework for cancer research. Lancet 1996; 348:
1149-51.
Baum M, Benson JR Current and future roles of adjuvant endocrine therapy in management of early carcinoma of the breast.
In Senn HJ, Gelber RD, Goldhirsch A, Thurlimann B, eds. Recent Results in CancerResearch-Adjuvant Therapy of Breast Cancer. Heidelberg:
Springer, 1996:215-226.
Controlled trial of tamoxifen as adjuvant agent in management of Early Breast Cancer. Interim analysis at
four years by the Nolvadex Adjuvant Trial Orginisation. Baum M, Brinkley DM, Dossett JA, et al The Lancet Feb. 5th ,1983; 257- 261
Home | Elsevier Sites | Privacy Policy | Terms and Conditions | Feedback | Site Map | A Reed Elsevier Company